IP Library Granted Patent US 10,745,672
Granted Patent B2
US 10,745,672 · App. 16/252,216 · Granted Aug 18, 2020

Method of producing a polypeptide or virus of interest in a continuous cell culture

Inventors: Leopold Grillberger (Vienna, AT); Manfred Reiter (Vienna, AT); Daniel Fleischanderl (Vienna, AT)
Assignees: Baxalta Incorporated; Baxalta GmbH
C12N7/00C12N9/6489C12P21/02C12N2710/00052C12Y304/24087Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,745,672
App. No.
16/252,216
Granted
Aug 18, 2020
Kind
B2
Abstract

Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d −1 , and a cell density of less than about 2×10 7 cell/mL. Also described herein is a method for producing a polypeptide and/or virus of interest in a continuous cell culture, the method comprising culturing mammalian cells expressing the polypeptide and/or virus of interest in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d −1 , and a cell density of less than about 2×10 7 cell/mL; and recovering the polypeptide and/or virus of interest from medium of the cell culture system.

Claims (22)

1. A method for producing a polypeptide of interest in a continuous cell culture, said method comprising

(a) culturing mammalian cells genetically modified to express the polypeptide of interest in a continuous cell culture system, wherein said cell culture system has a dilution rate (D) of less than 0.6 d −1 , a ratio of the dilution rate to a specific growth rate (D/μ) of from 1.2 to 5, and a cell density of less than 5×10 6 cell/mL; and

(b) recovering the polypeptide of interest from culture medium removed from the cell culture system.

2. The method of claim 1 , wherein the cells are CHO cells.

3. The method of claim 1 , wherein the polypeptide of interest is a disintegrin-like and metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13) protein.

4. The method of claim 1 , wherein the culture system further comprises a cell retention device that produces a cell retention rate of from 50% to 90%.

5. The method of claim 1 , wherein said cells are cultured in a serum-free medium.

6. The method of claim 2 , wherein the polypeptide of interest is a disintegrin-like and metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13) protein.

7. The method of claim 2 , wherein the culture system further comprises a cell retention device that produces a cell retention rate of from 50% to 90%.

8. The method of claim 2 , wherein said cells are cultured in a serum-free medium.

9. The method of claim 3 , wherein the culture system further comprises a cell retention device that produces a cell retention rate of from 50% to 90%.

10. The method of claim 3 , wherein said cells are cultured in a serum-free medium.

11. The method of claim 4 , wherein said cells are cultured in a serum-free medium.

12. The method of claim 6 , wherein the culture system further comprises a cell retention device that produces a cell retention rate of from 50% to 90%.

13. The method of claim 6 , wherein said cells are cultured in a serum-free medium.

14. The method of claim 7 , wherein said cells are cultured in a serum-free medium.

15. The method of claim 9 , wherein said cells are cultured in a serum-free medium.

16. The method of claim 12 , wherein said cells are cultured in a serum-free medium.

17. The method of claim 1 , wherein said cell culture system has a specific growth rate of between 0.15 d −1 and 0.3 d −1 .

18. The method of claim 1 , wherein said cells are cultured in said cell culture system for more than 40 days.

19. The method of claim 4 , wherein said cell retention device comprises a macroporous microcarrier.

20. The method of claim 1 , wherein said cells are cultured in at least 250 L of medium.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055188/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2020
From: GRILLBERGER, LEOPOLD; REITER, MANFRED; FLEISCHANDERL, DANIEL
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 051646/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2020
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 051724/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2020
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 051725/0001 →